A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients.

ABSTRACT:

Objective

Anlotinib is a multitarget anti-angiogenic drug that combined with temozolomide (TMZ) can effectively prolongs the overall survival (OS) of recurrent malignant glioma(rMG),but some patients do not respond to anlotinib combined with TMZ. These patients were associated with a worse prognosis and lack effective identification methods. Therefore, it is necessary to differentiate patients who may have good response to anlotinb in combination with TMZ from those who are not, in order to provide personalized targeted therapies.

Methods

Fifty three rMG patients (42 in training cohort and 11 in testing cohort) receiving anlotinib combined with TMZ were enrolled. A total of 3668 radiomics features were extracted from the recurrent MRI images. Radiomics features are reduced a

SUBMITTER: Li Y 

PROVIDER: S-EPMC10447352 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature